Defunct Company
Total Trials
12
As Lead Sponsor
11
As Collaborator
1
Total Enrollment
604
NCT00219648
Two-Stage Study to Assess the Efficacy and Safety of 12 Weeks of Treatment With PEP03 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Phase: Phase 2
Role: Lead Sponsor
Start: Sep 30, 2004
Completion: Not specified
NCT02884128
A Study of PEP02 in Combination With 5-fluorouracil (5-FU) and Leucovorin (LV) in Advanced Solid Tumors
Phase: Phase 1
Start: Jan 31, 2006
Completion: Jul 31, 2010
NCT00813072
Study of PEP02, Irinotecan or Docetaxel in Gastric or Gastroesophageal Junction Adenocarcinoma
Start: Nov 30, 2007
Completion: Dec 31, 2010
NCT00813163
Study of PEP02 as a Second Line Therapy for Metastatic Pancreatic Cancer
Start: Jan 31, 2009
Completion: Jul 31, 2012
NCT00940758
Phase I and Pharmacokinetic Study of Biweekly PEP02 in mCRC Refractory to 1st-line Oxaliplatin Base Therapy
Start: Jun 30, 2009
Completion: Jun 30, 2014
NCT02379845
NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating Randomized Patients in Two Arms With Soft Tissue Sarcoma of the Extremity and Trunk Wall
Phase: Phase 2/3
Role: Collaborator
Start: Mar 3, 2015
Completion: Sep 20, 2020
NCT02465593
A Study of PEP503(Radio-enhancer) With Radiotherapy and Chemotherapy for Patients With Rectal Cancer
Phase: Phase 1/2
Start: Jun 30, 2015
Completion: Jul 28, 2021
NCT02901483
A Study of PEP503 With Radiotherapy in Combination With Concurrent Chemotherapy for Patients With Head and Neck Cancer
Start: Oct 11, 2016
Completion: Aug 17, 2020
NCT03810742
Nanoliposomal Irinotecan (Nal-IRI, ONIVYDE®) in Combination With TAS-102 (LONSURF®) in Refractory Solid Tumors
Start: Mar 5, 2019
Completion: Oct 25, 2023
NCT05659732
A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients With Advanced Cancer
Start: Jul 17, 2023
Completion: Dec 31, 2026
NCT05983523
A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients with Advanced or Metastatic Solid Tumors
Start: Mar 27, 2024
Completion: Aug 31, 2027
NCT06973863
A Study of PEP08 in Patients With MTAP-Del Advanced or Metastatic Solid Tumors
Start: Sep 15, 2025
Completion: Mar 31, 2028